305 related articles for article (PubMed ID: 25179834)
21. Erythropoietic Protoporphyria and X-Linked Protoporphyria: pathophysiology, genetics, clinical manifestations, and management.
Balwani M
Mol Genet Metab; 2019 Nov; 128(3):298-303. PubMed ID: 30704898
[TBL] [Abstract][Full Text] [Related]
22. Molecular epidemiology of erythropoietic protoporphyria in the U.K.
Whatley SD; Mason NG; Holme SA; Anstey AV; Elder GH; Badminton MN
Br J Dermatol; 2010 Mar; 162(3):642-6. PubMed ID: 20105171
[TBL] [Abstract][Full Text] [Related]
23. Clinical, Biochemical, and Genetic Characterization of North American Patients With Erythropoietic Protoporphyria and X-linked Protoporphyria.
Balwani M; Naik H; Anderson KE; Bissell DM; Bloomer J; Bonkovsky HL; Phillips JD; Overbey JR; Wang B; Singal AK; Liu LU; Desnick RJ
JAMA Dermatol; 2017 Aug; 153(8):789-796. PubMed ID: 28614581
[TBL] [Abstract][Full Text] [Related]
24. A Novel Mutation in the FECH Gene in a Czech Family with Erythropoietic Protoporphyria and a Population Study of IVS3-48C Variant Contributing to the Disease.
Farrag MS; Kučerová J; Šlachtová L; Šeda O; Šperl J; Martásek P
Folia Biol (Praha); 2015; 61(6):227-32. PubMed ID: 26789144
[TBL] [Abstract][Full Text] [Related]
25. Erythroid-Progenitor-Targeted Gene Therapy Using Bifunctional TFR1 Ligand-Peptides in Human Erythropoietic Protoporphyria.
Mirmiran A; Schmitt C; Lefebvre T; Manceau H; Daher R; Oustric V; Poli A; Lacapère JJ; Moulouel B; Puy H; Karim Z; Peoc'h K; Lenglet H; Simonin S; Deybach JC; Nicolas G; Gouya L
Am J Hum Genet; 2019 Feb; 104(2):341-347. PubMed ID: 30712775
[TBL] [Abstract][Full Text] [Related]
26. Abnormal mitoferrin-1 expression in patients with erythropoietic protoporphyria.
Wang Y; Langer NB; Shaw GC; Yang G; Li L; Kaplan J; Paw BH; Bloomer JR
Exp Hematol; 2011 Jul; 39(7):784-94. PubMed ID: 21627978
[TBL] [Abstract][Full Text] [Related]
27. Microcytosis in Erythropoietic Protoporphyria.
Graziadei G; Duca L; Granata F; De Luca G; De Giovanni A; Brancaleoni V; Nava I; Di Pierro E
Front Physiol; 2022; 13():841050. PubMed ID: 35309058
[TBL] [Abstract][Full Text] [Related]
28. Protoporphyrin IX-induced phototoxicity: Mechanisms and therapeutics.
Hussain Z; Qi Q; Zhu J; Anderson KE; Ma X
Pharmacol Ther; 2023 Aug; 248():108487. PubMed ID: 37392940
[TBL] [Abstract][Full Text] [Related]
29. How I treat erythropoietic protoporphyria and X-linked protoporphyria.
Leaf RK; Dickey AK
Blood; 2023 Jun; 141(24):2921-2931. PubMed ID: 36898083
[TBL] [Abstract][Full Text] [Related]
30. Erythropoiesis and iron metabolism in dominant erythropoietic protoporphyria.
Holme SA; Worwood M; Anstey AV; Elder GH; Badminton MN
Blood; 2007 Dec; 110(12):4108-10. PubMed ID: 17804693
[TBL] [Abstract][Full Text] [Related]
31. Distribution of protoporphyrin IX in erythrocytes in a case of acquired erythropoietic protoporphyria.
Heerfordt IM; Fontenete S; Lerche CM; Wulf HC
Photodiagnosis Photodyn Ther; 2022 Mar; 37():102629. PubMed ID: 34798346
[TBL] [Abstract][Full Text] [Related]
32. Protoporphyrin accumulation by mitogen stimulated lymphocytes and protoporphyrinogen oxidase activity in patients with porphyria variegata and erythropoietic protoporphyria: evidence for deficiency of protoporphyrinogen oxidase and ferrochelatase in both diseases.
Siepker LJ; Kramer S
Br J Haematol; 1985 May; 60(1):65-74. PubMed ID: 3924091
[TBL] [Abstract][Full Text] [Related]
33. Repurposing of glycine transport inhibitors for the treatment of erythropoietic protoporphyria.
Halloy F; Iyer PS; Ghidini A; Lysenko V; Barman-Aksözen J; Grubenmann CP; Jucker J; Wildner-Verhey van Wijk N; Ruepp MD; Minder EI; Minder AE; Schneider-Yin X; Theocharides APA; Schümperli D; Hall J
Cell Chem Biol; 2021 Aug; 28(8):1221-1234.e6. PubMed ID: 33756123
[TBL] [Abstract][Full Text] [Related]
34. Cimetidine for erythropoietic protoporphyria.
Heerfordt IM; Lerche CM; Wulf HC
Photodiagnosis Photodyn Ther; 2022 Jun; 38():102793. PubMed ID: 35245673
[TBL] [Abstract][Full Text] [Related]
35. Iron, Heme Synthesis and Erythropoietic Porphyrias: A Complex Interplay.
Poli A; Schmitt C; Moulouel B; Mirmiran A; Puy H; Lefèbvre T; Gouya L
Metabolites; 2021 Nov; 11(12):. PubMed ID: 34940556
[TBL] [Abstract][Full Text] [Related]
36. Silencing of human ferrochelatase causes abundant protoporphyrin-IX accumulation in colon cancer.
Kemmner W; Wan K; Rüttinger S; Ebert B; Macdonald R; Klamm U; Moesta KT
FASEB J; 2008 Feb; 22(2):500-9. PubMed ID: 17875605
[TBL] [Abstract][Full Text] [Related]
37. Expression of murine 5-aminolevulinate synthase variants causes protoporphyrin IX accumulation and light-induced mammalian cell death.
Fratz EJ; Hunter GA; Ferreira GC
PLoS One; 2014; 9(4):e93078. PubMed ID: 24718052
[TBL] [Abstract][Full Text] [Related]
38. Erythropoietic protoporphyria a clinical and molecular study from Lebanon: Ferrochelatase a potential tumor suppressor gene in colon cancer.
Kadara H; Nemer G; Safi R; Rebeiz N; Daou L; Delbani D; Btadini W; Abbas O; Tofaili M; Bitar F; Kibbi AG; Shimomura Y; Kurban M
Clin Genet; 2017 Nov; 92(5):495-502. PubMed ID: 28075030
[TBL] [Abstract][Full Text] [Related]
39. Trends in erythrocyte protoporphyrin IX concentration by age, sex and season among patients with erythropoietic protoporphyria-20 years of follow-up.
Heerfordt IM; Lerche CM; Wulf HC
Photodiagnosis Photodyn Ther; 2020 Dec; 32():101928. PubMed ID: 32717453
[TBL] [Abstract][Full Text] [Related]
40. X-linked dominant protoporphyria: The first reported Japanese case.
Ninomiya Y; Kokunai Y; Tanizaki H; Akasaka E; Nakano H; Moriwaki S
J Dermatol; 2016 Apr; 43(4):414-8. PubMed ID: 26387792
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
